Aspire Growth Partners’s DexCom DXCM Stock Holding History

Aspire Growth Partners’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$285K	Sell	4,539 -39	-0.9%	-$2.72K	0.2%	96
2025 Q4	$304K	Sell	4,578 -261	-5%	-$16.9K	0.21%	92
2025 Q3	$326K	Sell	4,839 -17	-0.4%	-$1.34K	0.24%	90
2025 Q2	$424K	Sell	4,856 -65	-1%	-$5.09K	0.35%	71
2025 Q1	$410K	Buy	4,921 +87	+2%	+$7.1K	0.36%	68
2024 Q4	$376K	Buy	+4,834	New	+$358K	0.37%	69

Other funds holding DXCM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Aspire Growth Partners's DXCM Position: Q1 2026 in Review

Aspire Growth Partners reduced its DexCom (DXCM) stake by 0.85% in Q1 2026, selling an estimated $2.72K and leaving 4,539 shares worth $285K. The position accounts for 0.2% of the portfolio, ranked #96.

Aspire Growth Partners first reported a position in DXCM in Q4 2024 and has held it in 6 quarters since. The position peaked at $424K in Q2 2025. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

Aspire Growth Partners held 4,539 shares of DexCom worth $285K as of Q1 2026.
Aspire Growth Partners sold 39 DexCom shares in Q1 2026, an estimated $2.72K.
DexCom made up 0.2% of Aspire Growth Partners's portfolio in Q1 2026, its #96 holding.
Aspire Growth Partners first reported a position in DexCom in Q4 2024 and has held it in 6 quarters since.
Aspire Growth Partners's DexCom position peaked at $424K in Q2 2025.
956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on Aspire Growth Partners's 13F filing for Q1 2026, filed 17 Apr 2026.